Trial · NCT00117988

17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

NCT00117988, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2011-05-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma. Trials, record NCT00117988. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00117988

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
NCT number: NCT00117988
Status: Completed
Phases: Phase 2
Enrollment: 22 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Anaplastic Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma
Interventions: tanespimycin
First posted: 2005-07-11
Last updated: 2014-05-30
Results first posted: 2011-05-30

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Patients With Response	Baseline to time to best response; Every 6 weeks	Number of participants who experience complete response or partial response. Partial Response=\>50% decrease in lympho node masses. Complete Response=\>-75% decrease in lymph node masses.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Patients With Response	Baseline to time to best response; Every 6 weeks	Analysis was intention to treat (ITT). All participants with baseline and at least one post baseline target lesion measurement were included.	participants	NUMBER

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Patients With Response	17-AAG	Complete Response	0		participants
Number of Patients With Response	17-AAG	Partial Response	2		participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	17-AAG	22
Overall Study	COMPLETED	17-AAG	18
Overall Study	NOT COMPLETED	17-AAG	4

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhea	Gastrointestinal disorders	17-AAG	8	22
other	Fatigue	General disorders	17-AAG	7	22
other	Nausea	Gastrointestinal disorders	17-AAG	6	22
other	Pain	General disorders	17-AAG	5	22
other	Vomiting	Gastrointestinal disorders	17-AAG	5	22
other	Fever	General disorders	17-AAG	6	22
other	Neuropathy	Nervous system disorders	17-AAG	5	22
other	Hypomagnesemia	Metabolism and nutrition disorders	17-AAG	4	22
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	17-AAG	4	22
other	Blurred Vision	Eye disorders	17-AAG	3	22

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	17-AAG
Total, other adverse events	17-AAG	21	22
Total, serious adverse events	17-AAG	3	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants2

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
P30CA016672	The University of Texas MD Anderson Cancer Center Support Grant (CCSG)	KOONG, ALBERT	UNIVERSITY OF TX MD ANDERSON CAN CTR	NATIONAL CANCER INSTITUTE	1985 to 2026	NIH RePORTER
R21CA117070	Clinical Activity of 17-AAG in Lymphoma	YOUNES, ANAS	UNIVERSITY OF TX MD ANDERSON CAN CTR	NATIONAL CANCER INSTITUTE	2006 to 2007	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00117988

GET https://conductscience.org/api/trials/v1/NCT00117988/registered

API reference For AI assistants